

**THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.**

**MyHealthChecked PLC**  
("MyHealthChecked" or the "Company")

**Statement re. online comment**

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, notes online comment regarding the MyHealthChecked portfolio of at-home wellness tests now being available via a major UK retail partner.

As reported in the recent preliminary results on 3 April 2023, MHC is actively developing B2B2C customer relationships in preparation to launch an expanded portfolio of at-home wellness tests nationwide in 2023.

The Company is aware that MyHealthChecked products have been added temporarily and in draft to a retail partner's website, however no formal agreement has been signed and the Company remains at an advanced stage of negotiations. Further updates will be made to shareholders in due course.

**For further information contact:**

**MyHealthChecked PLC** [www.myhealthchecked.com](http://www.myhealthchecked.com)  
Penny McCormick, Chief Executive Officer via Walbrook PR

**SPARK Advisory Partners Limited (NOMAD)** Tel: +44 (0)20 3368 3550  
Neil Baldwin

**Dowgate Capital Limited (Broker)** Tel: +44 (0)20 3903 7715  
David Poutney / Nicholas Chambers

**Walbrook PR Ltd (Media & IR)** Tel: +44 (0)20 7933 8780 or [myhealthcheckedplc@walbrookpr.com](mailto:myhealthcheckedplc@walbrookpr.com)  
Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

**About MyHealthChecked PLC** (<https://investors.myhealthchecked.com/>)

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

**MyHealthChecked** is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests will also be made available online and will be viable for over-the-counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

STRUPUWWAUPWUMB